Drug profile · INN
copanlisib dihydrochloride
ALIQOPA
copanlisib dihydrochloride (ALIQOPA) is a pi3-kinase p110-alpha subunit inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — copanlisib dihydrochloride
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
copanlisib dihydrochloride (ALIQOPA) is a pi3-kinase p110-alpha subunit inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
PI3-kinase p110-alpha subunit inhibitor
Primary target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is copanlisib dihydrochloride?
copanlisib dihydrochloride (ALIQOPA) is a pi3-kinase p110-alpha subunit inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for copanlisib dihydrochloride?
ALIQOPA is a marketed brand name for copanlisib dihydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of copanlisib dihydrochloride?
copanlisib dihydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.